Utilizing our Immunotherapy Platform we intend to develop a number of pipeline candidates. These product candidates are in various phases of developmet, addressing a diverse number of pathogen-related, allergic or malignant diseases.
For example, allergies are caused by a pathogenic Th2-type immune response that can be induced by a diverse number of allergens. We believe that our DermAll Products will suppress pathogenic immune responses in allergic people by boosting allergen-specific Th1-type immune responses. This new mechanism is expected to restore a balanced Th1/Th2 immunity that is normally characteristic for people who do not have any allergic disease. The DermAll Product Portfolio will target several different allergies. Our first target for this indication will be House Dust Mite (HDM), as we have already collected preclinical animal data suggesting that DermAll-HDM treatment can suppress allergic sneezing by balancing Th1/Th2 immunity.
Our candidate immunotherapies in research and developmet include: